Quantification of cortisol and 6 beta-hydroxycortisol in human urine by LC-MS/MS, and gender-specific evaluation of the metabolic ratio as biomarker of CYP3A activity

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 878, Issue 1, 2009, Pages 97-101

  Lutz, Ursula ^a   Bittner, Nataly ^a   Ufer, Mike ^b   Lutz, Werner K ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Cortisol; CYP3A; Gender; Humans; Metabolite profiling; Phenotyping; Urine

Indexed keywords

CAUCASIANS; CLINICAL SETTINGS; COLUMN SWITCHING; CONCENTRATION OF; CYTOCHROME P450; ENZYME INDUCTION; GENETIC DIFFERENCES; HUMAN URINE; INTERNAL STANDARDS; LC-MS/MS; METABOLITE PROFILING; NON-INVASIVE; PHARMACOTHERAPIES; PHENOTYPING; SAMPLE CLEAN-UP;

BIOMARKERS; BODY FLUIDS; DRUG INTERACTIONS; ENZYMES; ISOTOPES; METABOLISM; METABOLITES;

ENZYME INHIBITION;

6BETA HYDROXYHYDROCORTISONE; BIOLOGICAL MARKER; CYTOCHROME P450 3A; HYDROCORTISONE;

ADULT; ARTICLE; BIOTECHNOLOGY; CHEMICAL STRUCTURE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENETIC DIFFERENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OXIDATION; PRIORITY JOURNAL; SEX DIFFERENCE; TANDEM MASS SPECTROMETRY; URINALYSIS; VALIDATION STUDY;

ADULT; BIOLOGICAL MARKERS; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PHENOTYPE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEX FACTORS; STATISTICS, NONPARAMETRIC; TANDEM MASS SPECTROMETRY;

EID: 71149090173     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2009.11.023     Document Type: Article

References (25)

1. Thummel K.E., and Wilkinson G.R. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 389
2. Ingelman-Sundberg M., Sim S.C., Gomez A., and Rodriguez-Antona C. Pharmacol. Ther. 116 (2007) 496
3. Liu Y.T., Hao H.P., Liu C.X., Wang G.J., and Xie H.G. Drug Metab. Rev. 39 (2007) 699
4. Wilkinson G.R. J. Pharmacokinet. Biopharm. 24 (1996) 475
5. Guengerich F.P. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 1
6. Zhou S.F. Curr. Drug Metab. 9 (2008) 310
7. Streetman D.S., Bertino Jr. J.S., and Nafziger A.N. Pharmacogenetics 10 (2000) 187
8. Watkins P.B. Pharmacogenetics 4 (1994) 171
9. Galteau M.M., and Shamsa F. Eur. J. Clin. Pharmacol. 59 (2003) 713
10. Barrett Y.C., Akinsanya B., Chang S.Y., and Vesterqvist O. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 821 (2005) 159
11. Matuszewski B.K., Constanzer M.L., and Chavez-Eng C.M. Anal. Chem. 70 (1998) 882
12. Stokvis E., Rosing H., and Beijnen J.H. Rapid Commun. Mass Spectrom. 19 (2005) 401
13. Brink A., Lutz U., Volkel W., and Lutz W.K. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 830 (2006) 255
14. Suzuki A., Shibasaki H., Kasuya Y., and Furuta T. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 794 (2003) 373
15. Turpeinen U., and Stenman U.H. Scand. J. Clin. Lab. Invest. 63 (2003) 143
16. Duxbury K., Owen L., Gillingwater S., and Keevil B. Ann. Clin. Biochem. 45 (2008) 210
17. FDA. Guidance for Industry: Bioanalytical Method Validation (2001), U.S. Food and Drug Administration
18. Ohno M., Yamaguchi I., Saiki K., Yamamoto I., and Azuma J. J. Chromatogr. B: Biomed. Sci. Appl. 746 (2000) 95
19. Lykkesfeldt J., Loft S., and Poulsen H.E. J. Chromatogr. B: Biomed. Appl. 660 (1994) 23
20. Inagaki K., Inagaki M., Kataoka T., Sekido I., Gill M.A., and Nishida M. Ther. Drug Monit. 24 (2002) 722
21. Palermo M., Gomez-Sanchez C., Roitman E., and Shackleton C.H. Steroids 61 (1996) 583
22. Watkins P.B., Turgeon D.K., Saenger P., Lown K.S., Kolars J.C., Hamilton T., Fishman K., Guzelian P.S., and Voorhees J.J. Clin. Pharmacol. Ther. 52 (1992) 265
23. Anderson G.D. Int. Rev. Neurobiol. 83 (2008) 1
24. Greenblatt D.J., and von Moltke L.L. J. Clin. Pharmacol. 48 (2008) 1350
25. Dresser G.K., and Bailey D.G. Eur. J. Clin. Invest. 33 Suppl 2 (2003) 10